| Patients n | 226 |
| Females | 157 (70) |
| Age years | 55.6±14 |
| Aetiology of PH | |
| Group 1: PAH | |
| Idiopathic | 89 (40) |
| Congenital heart disease | 50 (22) |
| Connective tissue disease | 43 (19) |
| Heritable | 3 (1) |
| Portal hypertension | 1 (0.5) |
| Group 2: PH left heart disease | 1 (0.5) |
| Group 3: PH lung | 1 (0.5) |
| Group 4: CTEPH | 36 (16) |
| Group 5: neurofibromatosis and sarcoidosis | 2 (1) |
| PH therapy | |
| Monotherapy | 125 (55) |
| Dual therapy | 78 (35) |
| Triple therapy | 11 (5) |
| Not recorded | 12 (5) |
| Route | |
| Inhaled iloprost | 20 (9) |
| i.v. iloprost | 8 (4) |
| i.v. treprostinil | 5 (2) |
| i.v. epoprostenol | 4 (2) |
| Continuous or as needed oxygen use | 87 (38) |
| 6MWD m# | 336±130 |
| Employment status | |
| Full-time work | 25 (11) |
| Part-time work | 31 (14) |
| Student | 2 (1) |
| Unemployed/retired | 168 (74) |
| WHO functional class | |
| I | 3 (1) |
| II | 73 (32) |
| III | 115 (51) |
| IV | 34 (15) |
| MLHFQ modified for PH | 47.8±25 |
| Hospital Anxiety and Depression scale | |
| Total | 13.3±7.5 |
| Anxiety | 6.9±4.4 |
| Depression | 6.3±3.9 |
| Dyspnoea-12 questionnaire | |
| Total | 12.8±9.8 |
| Physical | 8.5±5.8 |
| Affective | 4.4±4.6 |
Data are presented as n (%) or mean±sd, unless otherwise stated. PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic PH; 6MWD: 6-min walk distance; WHO: World Health Organization; MLHFQ: Minnesota Living with Heart Failure Questionnaire. #: n=98, patients attending the Sheffield Pulmonary Vascular Disease Unit, Sheffield, UK (n=66) underwent exercise testing with the incremental shuttle walking test and did not perform the 6MWD.